NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD, founded in 2015, is a mid-sized nonprofit in the Diseases & Disorders sector that reported $44.8M in total revenue in fiscal year 2024. Revenue grew 9% year-over-year, indicating healthy expansion. The organization ran a surplus of $8.7M, a strong 19% operating margin.
PARTNER WITH SCIENTISTS TO ACCELERATE RESEARCH THAT WILL TRANSFORM THE PREVENTION, DIAGNOSIS, AND TREATMENT OF CANCER THROUGH GROUND BREAKING SCIENCE CARRIED OUT BY INDIVIDUAL INVESTIGATORS, MULTIDISCIPLINARY TEAMS, AND EARLY STAGE COMPANIES IN THE U.S AND ABROAD.
THE FOUNDATION'S GRANTS REWARD INNOVATIVE THINKING THAT ADVANCES THE UNDERSTANDING OF CANCER BIOLOGY AND IMPROVES ONCOLOGY TREATMENT PARADIGMS. THE FOUNDATION SUPPORTS INDIVIDUAL INVESTIGATORS, AS...
THE FOUNDATION'S GRANTS REWARD INNOVATIVE THINKING THAT ADVANCES THE UNDERSTANDING OF CANCER BIOLOGY AND IMPROVES ONCOLOGY TREATMENT PARADIGMS. THE FOUNDATION SUPPORTS INDIVIDUAL INVESTIGATORS, AS WELL AS MULTIDISCIPLINARY COLLABORATIVE TEAMS CONDUCTING RESEARCH ACROSS CANCER TYPES. THE GRANTEES BECOME PART OF THE FOUNDATION'S NETWORK OF THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TECHNOLOGICAL INNOVATION. GRANT SUBMISSIONS UNDERGO RIGOROUS PEER REVIEW BY THE FOUNDATION'S SCIENTIFIC ADVISORY COMMITTEE OR RECOMMENDED SUBJECT MATTER EXPERTS AND ARE HELD TO THE STRICTEST STANDARDS OF SCIENTIFIC EXCELLENCE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $44,772,901 | $40,937,632 | +0.1% |
| Expenses | $36,066,750 | $35,209,497 | +0.0% |
| Net Income | $8,706,151 | $5,728,135 | +0.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ALEX KNASTER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROSS LEVINE | DIRECTOR | 1.00 |
Director
|
$10,000 | $0 | $10,000 |
| NICOLA MENDEHLSON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| PAUL POSPISIL | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| OTMAR D WIESTLER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| RAYMOND DUBOIS | EXECUTIVE CHAIRMAN OF THE BOARD | 24.00 |
Officer
Director
|
$560,000 | $0 | $560,000 |
| RYAN SCHOENFELD | CHIEF EXECUTIVE OFFICER | 40.00 |
Officer
|
$506,697 | $54,667 | $561,364 |
| IAN LESSER | DIRECTOR FINANCE & ADMINISTRATION | 40.00 |
Officer
|
$172,733 | $42,983 | $215,716 |
| ANNA TURETSKY TO 724 | PRINCIPAL, VENTURE INVESTMENTS | 40.00 |
Key Emp
|
$327,122 | $21,607 | $348,729 |
| REBECCA BISH-CORNELISSEN | HEAD DISCOVERY/PRE-CLINICAL RESEARCH | 40.00 |
Highest
|
$310,646 | $51,139 | $361,785 |
| AMY FEHIR | HEAD OF DEVELOPMENT | 40.00 |
Highest
|
$215,995 | $30,535 | $246,530 |
| REBECCA LIU | DIRECTOR, GRANTS ADMINISTRATION | 40.00 |
Highest
|
$197,094 | $34,568 | $231,662 |
| MICHAEL CARLETON | SENIOR SCIENTIFIC DIRECTOR | 40.00 |
Highest
|
$175,776 | $47,706 | $223,482 |
| ROBERT MAGIN | ASSOCIATE SCIENTIFIC DIRECTOR | 40.00 |
Highest
|
$169,179 | $20,443 | $189,622 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $44,772,901 | $36,066,750 | $105,459,714 | $8,706,151 |
| 2023 | $40,937,632 | $35,209,497 | $104,492,388 | $5,728,135 |
| 2022 | $55,345,494 | $38,014,606 | $110,652,350 | $17,330,888 |
| 2021 | $37,486,883 | $35,686,709 | $107,551,757 | $1,800,174 |
| 2020 | $40,176,299 | $21,645,747 | $109,005,993 | $18,530,552 |
| 2019 | $80,534,924 | $47,346,929 | $90,919,630 | $33,187,995 |
| 2018 | $40,519,118 | $38,540,021 | $33,818,430 | $1,979,097 |
Compare THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD with other nonprofits in New York and across the country.